Daiichi Sankyo soars on $22bn Merck cancer drugs deal
Shares in Japan's Daiichi Sankyo soared on Friday after the pharma group announced a major cancer drug deal with US giant Merck worth up to $22 billion.
Oct 20, 2023
0
52
Amino Acid, Peptide, or Protein: trastuzumab deruxtecan
Medical news and research articles
Systemic treatment for brain metastasis in HER2-positive advanced breast cancer
A new editorial paper titled "Systemic treatment for brain metastasis in HER2- positive advanced breast cancer: what have we learned so far?" has been published in Oncotarget.
Sep 13, 2023
0
63
HER2-targeted antibody drug conjugate shows strong anti-tumor activity and durable responses across multiple tumors
In a new study of trastuzumab deruxtecan, a HER2-targeted antibody drug conjugate, researchers observed encouraging responses and long-lasting clinical benefit in several tumor types. These data from an interim analysis of ...
Jun 5, 2023
0
46
T-DXd yields superior outcomes over chemotherapy-based regimens in patients previously treated with T-DM1
Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastatic breast cancer previously treated ...
Dec 7, 2022
0
31
Neoadjuvant trastuzumab deruxtecan shows clinical activity in patients with HER2-low breast cancer
Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in the neoadjuvant setting had an overall response rate of 75 percent in the absence of anastrozole ...
Dec 7, 2022
0
41
T-DXd yields longer overall survival than T-DM1 in patients with HER2-positive metastatic breast cancer
Second-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer, according to updated ...
Dec 7, 2022
0
23
HER2-low metastatic breast cancer patients report preserved quality of life with trastuzumab deruxtecan treatment
Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer reported that the treatment maintained their quality of life (QoL) compared to conventional ...
Sep 12, 2022
0
43
Top-selling drug Farxiga sees potential to reach more patients
One of AstraZeneca Plc's top-selling drugs Farxiga, a diabetes treatment, is beneficial to a wider pool of patients than previously indicated, a study shows, bolstering the product's blockbuster potential.
Aug 29, 2022
0
161
Prompt recognition and treatment found effective for lung disease in patients who received new drug for advanced cancer
Lung disease caused by a new drug for cancers—including metastatic or advanced breast cancer—can be effectively treated using approaches that focus on early detection and prompt management, according to a study published ...
Aug 11, 2022
0
87
FDA approves first targeted therapy for HER2-low breast cancer
The U.S. Food and Drug Administration has approved Enhertu (am-trastuzumab-deruxtecan-nxki), an intravenous infusion treatment for patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-low ...
Aug 9, 2022
0
94
